Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ANPMF > SEC Filings for ANPMF > Form 8-K on 26-Mar-2013All Recent SEC Filings

Show all filings for ANGIOTECH PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for ANGIOTECH PHARMACEUTICALS INC


26-Mar-2013

Entry into a Material Definitive Agreement, Other Events, Financial


Item 1.01. Entry Into Material Definitive Agreement.

Stock Purchase Agreement

On March 22, 2013, Angiotech Pharmaceuticals, Inc., a corporation formed under the laws of British Columbia (the "Company"), Angiotech International AG, a Swiss corporation ("AIAG"), and Angiotech Pharmaceuticals (US), Inc., a Washington corporation ("AUS" and, collectively with the Company and AIAG, the "Sellers") entered into a Stock Purchase Agreement dated March 22, 2013 (the "SPA") with Argon Medical Devices Holdings, Inc., a Delaware corporation ("Argon Holdco"), Argon Medical Devices, Inc., a Delaware corporation ("Argon"), and Argon Medical Devices Netherlands B.V., a private company with limited liability incorporated under the laws of the Netherlands ("Argon Netherlands" and, collectively with Argon, "Buyers"). AIAG and AUS are subsidiaries of the Company.

Pursuant to the terms of the SPA, the Sellers agreed to sell to Buyers substantially all corporate entities, manufacturing, commercial and administrative operations relating to the Company's Interventional Products business for $362.5 million in cash, subject to a post-closing working capital adjustment. The Sellers will receive $347.5 million upon the close of the transaction, and $15 million shall be retained in escrow for a period of 12 months to secure indemnification obligations of the Sellers.

The completion of the transactions described in the SPA (the "Transaction") is subject to various conditions, including, among others, the termination or expiration of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The completion of the Transaction is also subject to approval of the Company's shareholders. Shareholders representing approximately 70% of the Company's outstanding shares have signed voting agreements in connection with the Transaction, agreeing to vote their shares in favor of the Transaction. Subject to the satisfaction or waiver of conditions in the SPA, the Company expects the transaction to close by the end of April 2013.



Item 8.01. Other Events.

On March 25, 2013, the Company issued a press release to announce the Transaction. The press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are filed herewith:

Exhibit Description

99.1 Press Release, dated March 25, 2013.


  Add ANPMF to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ANPMF - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.